[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"LEO Pharma\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":89},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100540041","phase-3-a-trial-to-evaluate-the-efficacy-and-safety-of-tralokinumab-in-combination-with-topical-corticosteroids-in-children-and-infants-with-moderate-to-severe-atopic-dermatitis-100540041",false,"NCT06311682","A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis","A Phase 3 Multi-center Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children (Age 2 to \u003C12 Years) and Infants (Age 6 Months to \u003C2 Years) With Moderate-to-severe Atopic Dermatitis. The Trial is Randomized, Double-blind, Placebo-controlled, and Parallel-group for Children (Age 2 to \u003C12 Years) and Open-label and Single-group for Infants (Age 6 Months to \u003C2 Years)","TRAPEDS 2","Inclusion Criteria:\n\n* Age 6 months to \\\u003C12 years at screening.\n* Body weight ≥9 kg at screening.\n* Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD.\n* History of AD for: ≥12 months for subjects aged ≥6 years at screening and ≥3 months for subjects aged 6 months to \\\u003C6 years at screening.\n* Documented inadequate response to mid-strength TCS within 6 months before the screening visit.\n* AD involvement of ≥10% body surface area at screening and baseline according to component A of SCORAD.\n* An EASI score of ≥16 at screening and baseline.\n* An IGA score of ≥3 at screening and baseline.\n* A Child Worst Itch NRS average score of ≥4 (subjects aged ≥6 years at screening) or a Scratch ObsRO average score of ≥4 (subjects aged \\\u003C6 years at screening) during the week prior to baseline.\n\nExclusion Criteria:\n\n* Treatment with the topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), topical phosphodiesterase-4 inhibitors (PDE-4), and topical Janus kinase inhibitors (JAK) within 1 week prior to baseline.\n* Treatment with bleach baths within 1 week prior to baseline.\n* Treatment with the immunomodulatory medications systemic immunosuppressive\u002Fimmunomodulating drugs (e.g. methotrexate, cyclosporine, azathioprine, mycophenolate mofetil, Janus kinase inhibitors) and systemic corticosteroids (excludes inhaled, ophthalmic, or intranasal delivery) within 4 weeks prior to baseline.\n* Use of tanning beds or phototherapy within 4 weeks prior to baseline.\n* Treatment with a live (attenuated) or non-live vaccine within 30 days prior to the baseline visit.\n* Active dermatologic conditions that may confound the diagnosis of AD or would interfere with assessment of treatment such as seborrheic dermatitis, active skin infection, scabies, cutaneous T cell lymphoma, or psoriasis.\n* Clinically significant active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antifungals or antiprotozoal within 2 weeks before the baseline visit.\n* History of past or current hepatitis B or C including a positive hepatitis B or C test at screening.","ALL","6 Months","11 Years",{"count":21,"type":22},195,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections \\[SC\\]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of assessments that rate the severity and extent of atopic dermatitis and its symptoms, as well as general health status and quality of life. The trial will last for up to 4 years. There will be visits every 2 weeks for the first year and every 6 weeks thereafter. Some of the visits will be conducted by phone.\n\nThe study involves two different age groups: children aged 2 to under 12 years and infants aged 6 months to under 2 years. This trial compares tralokinumab +TCS to placebo + TCS for children with moderate-to-severe AD and evaluates tralokinumab + TCS for infants with moderate-to-severe AD. Infants will not receive placebo. All subjects will go through a screening process, which is the first part of the trial and will last up to 4 weeks. During this period, it will be checked if the child or infant meets the criteria to participate in the trial.\n\nThe children will be randomly assigned to receive tralokinumab + TCS or placebo + TCS for the initial 16 weeks, with the treatment being double-blinded. During the first 16 weeks, children will have a 2 out of 3 chance of getting tralokinumab and a 1 out of 3 chance of getting placebo. Thereafter, all subjects will receive tralokinumab + TCS. The infants will receive tralokinumab + TCS as open-label treatment for the entire treatment period, meaning that the participants will know they are receiving tralokinumab. After stopping treatment, all participants will enter a 4-week safety follow-up period.",[28],"Atopic Dermatitis","RECRUITING","2026-06-24",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":35,"type":33},"2024-06-10",{"date":37,"type":22},"2028-04-28",{"name":39,"class":40},"LEO Pharma","INDUSTRY",72,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100618743","phase-3-a-52-week-trial-to-investigate-the-efficacy-and-safety-of-delgocitinib-cream-in-adult-participants-with-lichen-sclerosus-100618743","NCT07335588","A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus","A Phase 3, Double-blinded, Vehicle-controlled Trial to Investigate the Efficacy and Safety of Twice Daily Delgocitinib Cream in Adult Participants With Lichen Sclerosus During a 12-Week Initial Treatment Period Followed by a 40-Week Continuation Treatment Period","DELTA CARE 1","Inclusion Criteria\n\n1. Signed and dated informed consent has been obtained prior to any protocol-related procedures.\n2. Age ≥18 years at the time of signing informed consent.\n3. Participant is able to comply with clinic visits and trial requirements and procedures, as assessed by the investigator.\n4. Female participants or male participants (assigned sex at birth and has not had any gender affirming medical procedures to their genital area) with LS in the anogenital area, regardless of treatment history. The diagnosis must be based on typical clinical features and supported by biopsy. A biopsy must be taken if there is no previous documented biopsy to support the diagnosis.\n\n   Note: Participants who also have LS-affected areas outside the anogenital area are allowed to be enrolled but these areas will not be treated with investigational medicinal product (IMP). Participants with newly diagnosed LS can be included, as well as participants who have progressive LS (including existing architectural changes).\n5. Disease severity graded as mild to severe at screening and baseline according to IGA-LS score (ie, an IGA-LS score of ≥2).\n6. Female participants: A woman of childbearing potential (WOCBP) must agree to use a highly effective or acceptable form of birth control throughout the trial up until the last application of IMP. Male participants: Contraceptive requirements are not applicable for male participants.\n\nExclusion Criteria\n\n1. Participants with atypical presentation of LS in the anogenital area where the diagnosis is uncertain, or the suspicion of malignancy exists.\n2. Female participants: History of vulvar squamous cell carcinoma (SCC), including precursor lesions (eg, human papillomavirus-independent \\[HPV-I\\] vulvar intraepithelial neoplasia \\[VIN\\] and high-grade squamous intraepithelial lesion). Male participants: History of penile SCC, including precursor lesions.\n3. Female participants only: Participants with any abnormal cytology result at screening following a positive high-risk human papillomavirus (hrHPV) screening test.\n4. Active dermatologic or gynecologic conditions that could confound the diagnosis of LS or interfere with assessment of the IMP (eg, urinary incontinence-associated dermatitis, genital lichen planus, and genital psoriasis), as assessed by the investigator.\n5. Participants with severe urinary incontinence. Incontinence is considered severe if it occurs on most days and more than a few drops at a time.\n6. Female participants: Suspected clinically (or confirmed diagnostically) of having active infection in the anogenital area, including candidiasis, Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae, Mycoplasma genitalium, bacterial vaginosis, or herpes simplex. Participants who test positive for sexually transmitted disease (STD)\u002Fbacterial vaginosis (BV)\u002Fanogenital candidiasis during screening can be treated, and if repeat testing is negative, these participants can be enrolled. If treatment is needed, the screening period can be extended to 6 weeks to accommodate the treatment and washout requirements.\n\n   Male participants: Suspected clinically (or confirmed diagnostically) of having active infection in the anogenital area, including candidiasis, Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, or herpes simplex. Participants who test positive for STD\u002Fanogenital candidiasis during screening can be treated, and if repeat testing is negative, these participants can be enrolled. If treatment is needed, the screening period can be extended to 6 weeks to accommodate the treatment and washout requirements.\n7. Clinically significant infection within 4 weeks prior to baseline which, in the opinion of the investigator, may compromise the safety of the participant in the trial, interfere with evaluation of the IMP, or reduce the participant's ability to participate in the trial.\n\n   Clinically significant infections are defined as:\n   * A systemic infection.\n   * A serious skin infection requiring parenteral (intravenous or intramuscular) antibiotics, antiviral, or antifungal medication.\n8. History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus test at screening, or the participant taking antiretroviral medications as determined by medical history and\u002For participant's verbal report.\n9. Major surgery within 8 weeks prior to screening or planned in-patient surgery or hospitalization during the trial period.\n10. History of cancer:\n\n    • Female participants: Participants who have had basal cell carcinoma or localized SCC of the skin (outside the anogenital area), or in situ carcinoma of the cervix are eligible provided that curative therapy was successfully completed at least 12 months prior to screening.\n\n    Participants who have had other malignancies (except vulvar SCC) are eligible provided that the participant is in remission and curative therapy was completed at least 5 years prior to screening.\n\n    • Male participants: Participants who have had basal cell carcinoma or localized SCC of the skin (outside the anogenital area) are eligible provided that curative therapy was successfully completed at least 12 months prior to screening.\n\n    Participants who have had other malignancies (except penile SCC) are eligible provided that the participant is in remission and curative therapy was completed at least 5 years prior to screening.\n11. Positive hepatitis B surface antigen and\u002For hepatitis B core antibody and positive for hepatitis B virus deoxyribonucleic acid (participants who have tested positive for hepatitis B core antibody are eligible if tests for hepatitis B surface antigen and hepatitis B virus deoxyribonucleic acid are negative), or positive hepatitis C virus antibody serology confirmed by hepatitis C virus ribonucleic acid (RNA) at screening.\n12. Known or suspected hypersensitivity to any component(s) of the IMP(s).\n13. Any disorder which is not stable and according to the investigator could:\n\n    * Affect the safety of the participant throughout the trial.\n    * Hinder the participant's ability to complete the trial.\n\n    Examples include, but are not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, immunological, and psychiatric disorders, and major physical impairment.\n14. Any abnormal finding which according to the investigator may:\n\n    * Put the participant at risk because of their participation in the trial.\n    * Influence the participant's ability to complete the trial.\n\n    The abnormal finding must be clinically significant and observed during the screening period. Examples include abnormal findings in physical examination, vital signs, electrocardiogram (ECG), hematology, or biochemistry.\n15. Current or recent chronic alcohol or drug abuse, or any other condition associated with poor compliance as judged by the investigator.\n16. Female participants only: Women who are pregnant or lactating. For women of childbearing potential, a negative pregnancy test is required at screening.\n17. Systemic treatment with immunosuppressive drugs (eg, methotrexate, cyclosporine), immunomodulating drugs, retinoids, or corticosteroids within 4 weeks prior to baseline.\n18. Cutaneously applied treatment with immunomodulators (eg, topical calcineurin inhibitor \\[TCI\\]) or topical corticosteroid (TCS) on the anogenital area within 2 weeks before baseline.\n19. Use of systemic or topical Janus kinase (JAK) inhibitors (including delgocitinib) within 4 weeks before baseline.\n20. Systemic or cutaneous (applied in the anogenital area) use of antibiotics, antiparasitics, antivirals, or antifungals within 1 week before baseline.\n21. Treatment with any marketed biological therapy or investigational biologic agents:\n\n    * Any cell-depleting agent including but not limited to rituximab: within 6 months prior to baseline, or until the lymphocyte count returns to normal, whichever is longer.\n    * Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to baseline.\n22. Treatment with any non-marketed drug substance (that is, an agent that has not yet been made available for clinical use following registration) within 4 weeks prior to baseline or 5 half-lives, whichever is longer.\n23. Light-based therapy on the anogenital area and treatments with platelet-rich plasma within 4 weeks prior to baseline.\n24. Cutaneous treatments applied within 1 week before baseline in regions other than the anogenital area which could interfere with clinical trial evaluations or pose a safety concern.\n25. Other cutaneous therapies or therapeutic procedures on the anogenital area within 1 week before baseline.\n26. Surgical treatment for anogenital LS in the past 6 months or have not recovered fully from an earlier surgical procedure in the anogenital area.\n27. Female participants only: Participants who are receiving doses that are not stable for topical estrogens (\\\u003C4 weeks before screening), and hormonal contraceptives and hormone replacement therapy (HRT) medications (\\\u003C3 months before screening).\n28. Current participation in any other interventional clinical trial.\n29. Previously randomized in this clinical trial.\n30. Previously randomized in a clinical trial with delgocitinib.\n31. Clinically important laboratory abnormalities:\n\n    * Participants with alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) values ≥2×the upper limit of normal (ULN) with total bilirubin (BIL) ≥1.5×ULN (unless elevated BIL is related to Gilbert Meulengracht Syndrome).\n    * Participants with ALT and\u002For AST values ≥3×ULN.\n    * Participants with severe renal impairment (estimated glomerular filtration rate \\[eGFR\\]\\\u003C30 mL\u002Fmin\u002F1.73 m2).\n32. Employees of the trial site, or any other individuals directly involved with the planning or conduct of the trial, or immediate family members of such individuals.\n33. Participants who are legally institutionalized.\n34. Only applicable in France: Participant not affiliated with or not a beneficiary of a social security scheme.\n35. Male participants only: Participants who currently need or are expected during the entire study period to require any type of surgical treatment for LS (eg, circumcision, urethroplasty, adhesiolysis) or tool-assisted local treatment (eg, catheter, cotton swabs, applicators, dilators, etc.) for LS involving the urethra. Application of study treatment of the urethral meatus is allowed if it can be applied by the participant's hand or fingers only.","18 Years",{"count":52,"type":22},652,[25],"The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream compared with cream vehicle in the treatment of adult participants with mild to severe lichen sclerosus (LS). The researchers are focusing on female participants because LS is more likely to affect females compared to males.\n\nThe trial is conducted in 2 parts. Part 1 of the trial enrolls female participants with LS and results in the selection of the optimal dose for Part 2. The selected dose will then be evaluated in Part 2, which will enroll both female and male participants. Assessment of efficacy and safety of delgocitinib cream in male participants with LS will be evaluated in a substudy.\n\nFor each participant, the trial will last at least 55 weeks and up to 60 weeks.",[56],"Lichen Sclerosus","2026-06-08",{"date":59,"type":33},"2026-06-09",{"date":61,"type":33},"2026-05-01",{"date":63,"type":22},"2028-12-29",{"name":39,"class":40},7,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},"100593958","phase-2-a-16-week-trial-to-investigate-the-efficacy-and-safety-of-delgocitinib-cream-20-mgg-in-adult-participants-with-mild-to-severe-palmoplantar-pustulosis-100593958","NCT07013201","A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg\u002Fg in Adult Participants With Mild to Severe Palmoplantar Pustulosis","A Proof-of-concept Phase 2a, Double-blind, 2-arm Trial to Investigate the Efficacy and Safety of Twice Daily Delgocitinib Cream 20 mg\u002Fg Compared With Cream Vehicle During a 16-week Treatment Period in Adult Subjects With Mild to Severe Palmoplantar Pustulosis","Inclusion Criteria:\n\n* Signed and dated informed consent has been obtained prior to any protocol-related procedures.\n* Age 18 years or above at the time of informed consent signing.\n* Participant is able to comply with clinic visits and trial requirements and procedures, as assessed by the investigator.\n* Diagnosis of PPP in accordance with the consensus diagnostic criteria established by European Rare and Severe Psoriasis Expert Network: primary, persistent (\\>3 months duration), sterile, macroscopically visible pustules on the palms and\u002For soles, with or without plaque psoriasis elsewhere on the body.\n* Confirmed PPP by central evaluation of photographs taken at screening.\n* Mild to severe PPP current condition defined by:\n\n  * Disease duration of PPP of \\>6 months before randomisation.\n  * PPP-PGA of at least mild severity (PPP-PGA ≥2) at screening and baseline.\n  * PPPASI ≥8 at screening and baseline.\n* Presence of ≥5 well-demarcated fresh pustules (white or yellow pustules) in total across all affected areas at screening and baseline.\n* Participants with prior experiences of inadequate response with topical corticosteroid(s) (TCS) or for whom TCS are inadvisable, as judged by the investigators.\n* A woman of childbearing potential must use an acceptable form of birth control throughout the trial up until the last administration of investigational medicinal product (IMP).\n\nExclusion Criteria:\n\n* Presence or known history of drug-induced PPP (e.g., a new onset of PPP or an exacerbation of PPP from beta blockers, calcium channel blockers, lithium, or biologic therapy including infliximab, adalimumab, or etanercept).\n* Presence of acrodermatitis continua of Hallopeau.\n* Active dermatologic condition that could confound the diagnosis of PPP or interfere with assessment of the IMP, as assessed by the investigator.\n* Clinically significant infection on the palms or soles.\n* Concurrent plaque psoriasis covering \\>5% of body surface area.\n* Clinically significant infection within 4 weeks prior to baseline, which, in the opinion of the investigator, may compromise the safety of the participant in the trial, interfere with evaluation of the IMP, or reduce the participant's ability to participate in the trial. Clinically significant infections are defined as:\n\n  * A systemic infection.\n  * A serious skin infection requiring parenteral (intravenous or intramuscular) antibiotics, antiviral, or antifungal medication.\n* History of any known primary immunodeficiency disorder, including a positive human immunodeficiency virus test at screening, or the participant taking antiretroviral medications as determined by medical history and\u002For the participant's verbal report.\n* Major surgery within 8 weeks prior to screening or planned in-patient surgery or hospitalisation during the trial period.\n* Any documented active or suspected malignancy, or history of malignancy within 5 years prior to screening, except basal cell carcinoma of the skin, localized squamous cell carcinoma of the skin, or in situ carcinoma of the cervix appropriately treated before the baseline visit.\n* Any disorder that is not stable and could:\n\n  * Affect the safety of the participant throughout the trial.\n  * Impede the participant's ability to complete the trial. Examples include, but are not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, immunological, and psychiatric disorders, as well as major physical impairment.\n* Any clinically significant abnormal finding occurring during the screening period and\u002For observed at the baseline visit that may put the participant at risk due to their participation in the trial or could influence the participant's ability to complete the trial.\n* Positive hepatitis B surface antigen and\u002For hepatitis B core antibody and positive hepatitis B virus DNA (participants who have tested positive for hepatitis B core antibody are eligible if tests for hepatitis B surface antigen and hepatitis B virus DNA are negative) or positive hepatitis C virus antibody serology confirmed by hepatitis C virus RNA at screening.\n* Known or suspected hypersensitivity to any component(s) of the IMP.\n* Current or recent chronic alcohol or drug abuse, or any other condition associated with poor compliance as judged by the investigator.\n* Women who are pregnant or lactating.\n* Systemic treatment within 4 weeks prior to baseline with immunosuppressive drugs (e.g., methotrexate, cyclosporine, azathioprine), immunomodulating drugs, retinoids (e.g., acitretin), tyrosine kinase inhibitors, phosphodiesterase-4 inhibitors, or corticosteroids (steroid eye drops and inhaled or intranasal steroids in the doses recommended in the product prescribing information for the treatment of allergic conjunctivitis, asthma, or rhinitis are allowed).\n* Use of tanning beds or phototherapy (e.g., ultraviolet B \\[UVB\\], ultraviolet A1 \\[UVA1\\], psoralen ultraviolet A \\[PUVA\\]) on the palms or soles within 4 weeks prior to baseline.\n* Use of systemic or topical janus kinase inhibitors (including delgocitinib\u002FLEO 124249) within 4 weeks prior to baseline.\n* Cutaneously applied treatment with immunomodulators (e.g., phosphodiesterase-4 \\[PDE-4\\] inhibitors, pimecrolimus, tacrolimus, tapinarof, vitamin D3 derivatives) or TCS on the palms or soles within 2 weeks prior to baseline.\n* Use of systemic antibiotics or cutaneously applied antibiotics on the palms or soles within 2 weeks prior to baseline.\n* Other transdermal or cutaneously applied therapy on the palms or soles (except for the use of the participant's own non-medicated emollients) within 1 week prior to baseline.\n* Cutaneously applied treatments in regions other than the palms or soles, which could interfere with clinical trial evaluations or pose a safety concern (excluding treatments for psoriasis patches or other non-exclusionary skin conditions, if needed) within 1 week prior to baseline.\n* Treatment with any marketed biological therapy or investigational biologic agents:\n\n  * Any cell-depleting agents, including but not limited to rituximab: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer.\n  * Other biologics, including but not limited to secukinumab, ustekinumab, tildrakizumab, ixekizumab, risankizumab, guselkumab, and tumour necrosis factor (TNF)-alpha inhibitors: within 3 months or 5 half-lives, whichever is longer, prior to baseline.\n* Treatment with any non-marketed drug substance (i.e., an agent that has not yet been made available for clinical use following registration) within the last 4 weeks prior to baseline or 5 half-lives, whichever is longer.\n* Current participation in any other interventional clinical trial.\n* Previously randomised in this clinical trial.\n* Previously randomised in a clinical trial with delgocitinib.\n* Employees of the trial site, or any other individuals directly involved with the planning or conduct of the trial, or immediate family members of such individuals.",{"count":74,"type":22},135,[76],"PHASE2","The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg\u002Fg compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis (PPP). Total study duration for each participants will be approximately 18 weeks, for an approximate total of 9 visits.",[79],"Palmoplantar Pustulosis","2026-06-04",{"date":82,"type":33},"2026-06-05",{"date":84,"type":33},"2025-09-11",{"date":86,"type":22},"2026-12-14",{"name":39,"class":40},38,""]